PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders

Rhea-AI Summary

PharmaCyte Biotech (OTCQB: PMCB) will hold its Annual Meeting of Shareholders virtually on June 16, 2021, at 11:00 A.M. PDT. Shareholders should have received a Proxy Statement with four proposals to vote on, including a critical one for the development of its pancreatic cancer treatment. CEO Kenneth L. Waggoner emphasized the importance of voting 'yes' for ongoing viability and clinical progress. The meeting will provide updates on addressing FDA requests for the clinical hold on their pancreatic cancer therapy and discuss other company matters.

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box^®, announced today that this week’s Annual Meeting of Shareholders will be held virtually on Wednesday, June 16, 2021, at 11:00 A.M., Pacific Daylight Time at

https://www.virtualshareholdermeeting.com/PMCB2021

By now all PharmaCyte shareholders should have received a Proxy Statement with 4 separate proposals requiring shareholders to vote on each. If a shareholder has not received a Proxy Statement, please email Investor Relations at investorrelations@PharmaCyte.com and a Proxy Statement will be sent to you. Shareholders can vote electronically using the information in the Proxy Statement or by calling (201) 463-8535.

PharmaCyte’s Chief Executive Officer (CEO), Kenneth L. Waggoner, said of the importance of this vote prior to Wednesday’s Annual Meeting, “Each shareholder voting ‘yes’ on the proposals, especially Proposal No. 2, is critical for PharmaCyte to remain a viable company and for its pancreatic cancer treatment to remain in development and avoid being shelved. We encourage every shareholder to obtain and read the Proxy Statement and then participate in the vote.”

During the virtual meeting, the CEO will update shareholders on the latest work being done by PharmaCyte’s assembled scientific team to address the FDA’s requests related to the clinical hold on PharmaCyte’s treatment for locally advanced inoperable pancreatic cancer. Additionally, other company business will be addressed, including a discussion on the proposals set forth in the Proxy Statement and subsequent voting.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the Company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box^®.” This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also considering the use of genetically modified stem cells to treat diabetes. The encapsulation of the cell lines will be done using the Cell-in-a-Box^® technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward- looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005212/en/

FAQ

What is the date and time of PharmaCyte Biotech's Annual Meeting of Shareholders in 2021?

PharmaCyte Biotech's Annual Meeting of Shareholders will take place on June 16, 2021, at 11:00 A.M. Pacific Daylight Time.

Where can I find the link to attend PharmaCyte Biotech's virtual meeting?

The link to attend the virtual meeting is available at https://www.virtualshareholdermeeting.com/PMCB2021.

How many proposals will shareholders vote on during PharmaCyte's Annual Meeting?

Shareholders will vote on four separate proposals during PharmaCyte's Annual Meeting.

What did CEO Kenneth L. Waggoner say about the importance of voting on Proposal No. 2?

CEO Kenneth L. Waggoner stressed that voting 'yes' on Proposal No. 2 is crucial for PharmaCyte's viability and the continuation of its pancreatic cancer treatment.

What updates will be provided during PharmaCyte Biotech's Annual Meeting?

During the meeting, updates will be provided on PharmaCyte's efforts to address the FDA's requests regarding the clinical hold on its pancreatic cancer treatment.